Endlyz is supported by leading investors, including SV Health Investors’ Dementia Discovery Fund, Oxford Science Enterprises, ...
Orbital’s (second) Brown album is getting the super deluxe reissue treatment via London Records in the form of a 4LP boxset, ...
PHILADELPHIA, PA — Context Therapeutics Inc. has confirmed its presence at several prominent investor conferences scheduled ...
Zacks Investment Research on MSN4d
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.
The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...
Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback